Matthew Eden
Physician Assistant · Miami Beach, FLNPI 1609408343
Payments from drug & device makers
Across 286 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Insulet Corporation$1K
- Novo Nordisk$895
- Sanofi-aventis U.S. LLC$732
- Cequr Corporation$451
- Radius Health, Inc.$405
- plus $2K from 20 others
What the payments were for
- Food & beverage$7,222100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 71 | $1,448 |
| Insulet Corporation | 47 | $1,229 |
| Novo Nordisk | 45 | $895 |
| Sanofi-aventis U.S. LLC | 20 | $732 |
| Cequr Corporation | 3 | $451 |
| Radius Health, Inc. | 12 | $405 |
| Amneal Pharmaceuticals LLC | 16 | $303 |
| Recordati_rare_diseases_inc. | 11 | $288 |
| Tandem Diabetes Care, Inc. | 5 | $222 |
| Amgen | 10 | $197 |
| Boehringer Ingelheim | 8 | $193 |
| IBSA Pharma Inc. | 6 | $137 |
| Mannkind Corporation | 5 | $114 |
| Corcept Therapeutics | 5 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $108 |
| Kyowa Kirin, Inc. | 2 | $54 |
| Dexcom, Inc. | 3 | $52 |
| Sequel Med Tech, LLC | 2 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Madrigal Pharmaceuticals | 1 | $43 |
| Amphastar Pharmaceuticals, Inc. | 2 | $35 |
| Medtronic | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Bayer | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$428
- Omnipod$373
- TZIELD$328
- Tymlos$250
How this compares
$7,234 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 387 | $452,957 |
| JardianceEmpagliflozin | 229 | $209,432 |
| OzempicSemaglutide | 109 | $118,150 |
| RybelsusSemaglutide | 52 | $63,040 |
| FarxigaDapagliflozin Propanediol | 43 | $47,146 |
| TrulicityDulaglutide | 36 | $42,852 |
| TymlosAbaloparatide | 13 | $37,119 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $33,306 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 27 | $29,848 |
| JanuviaSitagliptin Phosphate | 39 | $29,830 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $24,461 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $21,518 |
| Repatha SureclickEvolocumab | 23 | $20,190 |
| TradjentaLinagliptin | 25 | $16,166 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $12,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,448 | $500,545459 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $193 | $236,920271 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $895 | $185,908181 claims |
| Radius Health, Inc.Tymlos | $405 | $37,11913 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $732 | $21,51825 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $303 | $3,444223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.
Other physician assistant in Miami Beach
- Richard MarshallPort Orange$988K
- Audrey BeckerSt Augustine$689K
- Kevin WilliamsTampa$647K
- Brian BonomoLecanto$559K
- Melissa SingletonOcala$482K
- Reeli ReinuMaitland$427K
- Jeanelle KingMiami$424K
- Risha BellomoOrlando$397K
- Jason BergerClearwater$344K
- Ashley MillerGainesville$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.